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Point-of-care HPV molecular diagnostics for a test-and-treat
model in high-risk HIV populations
Strategies for cervical cancer prevention and control
in low-income and middle-income countries (LMICs)
require concerted efforts to improve screening
and access to treatment, especially in high-risk HIV
populations. LMICs bear the largest burden of HIV
infection, human papillomavirus (HPV) infection is
common among HIV-infected women, risk of cervical
cancer is increased in women with HIV/AIDS, and HIV
clinics provide opportunities to screen and treat for
cervical cancer in this population.
A cluster randomised trial from India has shown that
one round of HPV screening reduced advanced cervical
cancer and mortality compared with the standard care
group, whereas the so-called see and treat method
(visual inspection of the cervix with acetic acid, VIA) did
not show such benefit.1 Furthermore, overtreatment and
undertreatment due to the low sensitivity and specificity
of the current screening tests are a real problem and they
reduce the impact of screening in health systems that are
already overstretched and under-resourced.
Implementation of the traditional Pap smear in national
screening programmes is not sustainable in underresourced LMIC settings with a limited skilled cytologist
workforce2 and where, despite a high prevalence of
cervical cancer,3 loss to follow-up and poor adherence
to treatment are major impediments for programmatic
success. The current WHO recommendation for HPV
testing as a primary cervical cancer screening tool has
been adopted by countries such as Kenya, where it forms
part of the national cancer screening guidelines.
However, a concern with the HPV screen-and-treat
approach is the overtreatment of high-risk HPVpositive women. There is a need for innovative pointof-care molecular diagnostic tools that are sensitive
and specific and can be integrated into primary
health settings in LMICs as screen-and-treat models.
These point-of-care platforms can further be used to
diagnose multiple conditions and monitor therapy on
a single device.4
There are multiple HPV point-of-care testing platforms
in the market (eg, the careHPV test, Qiagen), but none
of these has been fully validated in the clinical setting.
Devices such as the GeneXpert (Cepheid, Sunnyvale, CA,
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USA), which has been endorsed by WHO for molecular
diagnosis of tuberculosis and rifampicin resistance5
and which requires minimum training, have created
opportunities for disease diagnostic testing; GeneXpert
is currently the only validated HPV point-of-care device.
The GeneXpert, developed by Cepheid for rapid molecular
diagnostics,6 combines cartridge-based microfluidic
sample preparation with RT-PCR-based fluorescent
signal detection with the capacity to perform RNA
isolation, reverse transcription, and quantitative PCR in
about 35 min.8 To date, there are over 7000 GeneXpert
platforms globally, the majority of which are in lowincome and middle-income countries and are being used
almost exclusively for tuberculosis diagnosis.7
However, for the point-of-care HPV tests to be
adopted, they must be widely applicable, specifically in
high-risk HIV populations. In The Lancet Global Health,
Louise Kuhn and colleagues8 describe a clinical study
from South Africa and provide a comprehensive
background of the current limitation of the GeneXpert
for screening a high-risk HIV positive population.
They describe a novel modification of the test that
would increase the specificity of detecting cervical
intraepithelial neoplasia of grade 2 (CIN2+) on the
same device by up to 26% without compromising the
sensitivity of the test in high-risk HIV-positive women.
Furthermore, by restricting the channels to the eight
high-risk HPV genotypes (HPV 16, 18, 45, 31, 33, 35,
52, and 58), they demonstrate that specificity increased
by about 4·4% in the HIV-negative population and
by 17·1% in the HIV-positive population. The positive
predictive value increased by 2·2–3·6% for CIN2+.
Specificity is important in a screening test to avoid
overtreatment. New studies9 suggest that loop electro
surgical excision procedure (LEEP) might be better than
cryotherapy (ie, lower recurrence of CIN2+ lesions)
among HIV-infected women, but overtreatment with
LEEP might have worse consequences than cryotherapy
given the side-effects associated with LEEP such as
cervical stenosis and bleeding. A more specific test is
thus welcome. Kuhn and colleagues also suggest that
the HPV screen-and-treat method can leverage on the
VIA or Lugol’s Iodine (VILI) infrastructure already in
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For more on the burden of HIV
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place in many LMICs—a point that we agree with given
that minimal training is required to perform the HPV
test on the GeneXpert platform.
However, it is crucial that any new point-of-care test is
easy to perform, sensitive, and specific, and that it is not
vulnerable to user error like VIA, which has performed
poorly in LMICs (the test is subjective and requires
regular refresher training to maintain accuracy). The
new HPV test modification reported on the Gene Xpert
by Kuhn and colleagues8 might be able to overcome
this. But, before LMICs adopt point-of-care technologies
that can surpass fragile health systems and allow for
testing in the absence of traditional laboratory settings,
multiple implementation studies examining costeffectiveness, feasibility, and acceptability by healthcare workers and by women of HPV screen-and-treat
methods are needed. More importantly, it would be
useful to understand how HPV test specificity might be
affected by immune status, ART use, and age, as these
variables might reduce specificity of the test.10
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